Parabilis Medicines

Headlines · 1

1. Oct 23
   Verdine weighs AI’s drug-discovery value against capital pressure on biotech

   In a Huxiu interview, Harvard professor Gregory L. Verdine said AI benefits drug discovery by changing researchers’ work rather than replacing them. He also argued that AI offers faster and larger returns, while biotech lacks scale effects, making it harder for biotechnology to compete for venture investment. Verdine said Chinese innovation-drug companies remain focused mainly on best-in-class assets and need more long-term investment in novel targets. Tsinghua University pharmacy dean Qian Feng said overseas licensing has become a financing route for Chinese biotech companies struggling to raise capital domestically.

   虎嗅 AI · 🔥 0

Experience and discussion from the community

Share my Parabilis Medicines experienceAsk about Parabilis Medicines